Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 1/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 9/20 | 0.42 |
| ▸ | CSNK1E | P49674 | 5/20 | 0.40 |
| ▸ | CNR1 | P21554 | 3/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2887702 | 0.86 | CSNK1E (0.45) | CSNK1ECSNK1DGAA | |
| SCHEMBL2891520 | 0.86 | P2RX7 (0.46) | RBP4P2RX7 | |
| SCHEMBL2889100 | 0.85 | MEN1 (0.45) | RBP4P2RX7 | |
| SCHEMBL2889480 | 0.81 | P2RX7 (0.42) | RBP4P2RX7 | |
| SCHEMBL2894092 | 0.74 | MEN1 (0.45) | P2RX7GAA | |
| SCHEMBL5481400 | 0.73 | P2RX7 (0.37) | P2RX7 | |
| SCHEMBL2889747 | 0.73 | SCN9A (0.49) | — | |
| SCHEMBL12975581 | 0.73 | POLB (0.49) | P2RX7CNR1CNR2 | |
| SCHEMBL2889963 | 0.72 | ADRB1 (0.40) | — | |
| SCHEMBL5483719 | 0.71 | HTT (0.47) | P2RX7GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858800-B2 | Biaryl derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-12-28 | — | — | US | disclosed |
| US-7858800-B2 | Biaryl derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-12-28 | — | — | US | disclosed |
| US-7858800-B2 | Biaryl derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-12-28 | — | — | US | disclosed |
| US-20070191389-A1 | Biaryl derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| US-20070191389-A1 | Biaryl derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| US-20070191389-A1 | Biaryl derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1764362-A1 | BIARYL DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191389-A1 | Biaryl derivatives | GRM1, GRIN1, GRIN2B | RBP4 4190/4885P2RX7 1337/4885CSNK1E 602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.